Glycosaminoglycans: Sweet as Sugar Targets for Topical Skin Anti-Aging

Siew Tein Wang
Boon Hoe Neo
Richard J Betts
L’Oréal Research & Innovation, L’Oréal Singapore, Singapore

Abstract: Glycosaminoglycans (GAGs) are long, linear polysaccharides comprised of repeating disaccharide units with pleiotropic biological functions, with the non-sulfated GAG hyaluronic acid (HA), and sulfated GAGs dermatan sulfate, chondroitin sulfate, heparan sulfate, keratan sulfate, and to a lesser extent heparin all being expressed in skin. Their ability to regulate keratinocyte proliferation and differentiation, inflammatory processes and extracellular matrix composition and quality demonstrates their critical role in regulating skin physiology. Similarly, the water-binding properties of GAGs and structural qualities, particularly for HA, are crucial for maintaining proper skin form and hydration. The biological importance of GAGs, as well as extensive evidence that their properties and functions are altered in both chronological and extrinsic skin aging, makes them highly promising targets to improve cosmetic skin quality. Within the present review, we examine the cutaneous biological activity of GAGs alongside the protein complexes they form called proteoglycans and summarize the age-related changes of these molecules in skin. We also examine current topical interventional approaches to modulate GAGs for improved skin quality such as direct exogenous administration of GAGs, with a particular interest in strategies targeted at potentiating GAG levels in skin through either attenuating GAG degradation or increasing GAG production.

Keywords: proteoglycan, growth factor, retinoic acid, hyaluronic acid, C-xyloside

Introduction
Significant advances within the field of aesthetic medicine have been made over the past 20 years, with effective treatments such as Botox, skin peels and laser treatments offering readily perceived efficacy against age-associated decline in skin quality. While medical approaches have proved successful, these are generally not the first resort for consumers. Imparting high levels of efficacy for more accessible cosmetic approaches for anti-aging, especially those focused around small molecules or natural extracts, is not without challenges. A key issue for successful molecule/extract screening and development is to select the most appropriate biological targets, with strategies aimed at pathways exhibiting important biological activity and/or differential regulation through the aging process most likely to offer clinically perceivable benefits.

Glycosaminoglycans are a well-recognized skincare target due to their high endogenous expression in skin, pleiotropic biological action and attenuated expression/activity within aged skin. The unsulfated GAG hyaluronic acid (HA) features particularly prominently within skincare, however sulfated GAGs such as chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), and keratan
sulfate (KS) also possess strong biological activity that can be modulated to improve skin quality. Within the present review we aim to examine the scientific territory concerning GAGs in skin, as well as their associated proteoglycans. We examine current raw material approaches aimed at leveraging GAGs to improve skin quality, with particular interest in strategies concerning sulfated GAGs and increasing endogenous GAG production within skin.

## Glycosaminoglycans

Glycosaminoglycans are long, linear polysaccharides comprised of repeating disaccharide units and are ubiquitous within the skin, being present intracellularly, on the cell surface and within the extracellular matrix (ECM). There are six key types of GAGs; (1) CS, (2) DS, (3) HS, (4) heparin, (5) KS, and (6) hyaluronic acid (HA).

Hyaluronic acid is an atypical GAG, unique by virtue of being non-sulfated, of large molecular size, and undergoing molecular assembly at the cytoplasm rather than the Golgi apparatus. All others are collectively referred to as sulfated GAGs.

Sulfated GAGs are synthesized in the rough endoplasmic reticulum on which a serine amino acid (asparagine or threonine possible for KS) of the core protein is attached with a xylose residue, followed by two galactose residues and a single glucuronic acid molecule. This four molecule group is known as the tetrasaccharide linker and constitutes the stem oligosaccharide structure common to all sulfated GAGs except KS, on which repeating disaccharide units are added to form different GAG types. These units are comprised of uronic acid family members glucuronic acid or iduronic acid, or the monosaccharide galactose for KS molecules, and a unit of an amino sugar (either N-acetylgalactosamine (GlcNAc), N-acetylglucosamine (GlcNAc) or glucosamine (GlcN)), with the GAG chains reaching up to 100 repeating units in length for KS, CS, and DS, or up to 200 for HS (Figure 1A; Table 1). Post-translational modification of sulfated GAG by both epimerization and sulfation follows characteristic patterns but creates a high degree of structural GAG variation and complexity of GAG biological activity.

Within skin, CS, DS, KS, and HS are of particular importance. Chondroitin sulfate and DS are generally considered to be of the same family, with CS composed of repeated disaccharide units consisting of GlcNAc and glucuronic acid. The glucuronic acid residues can be further epimerized to iduronic acid, with the resulting structure being DS. Chondroitin sulfate and DS chains can be sulfated at the 4-O position on GalNAc (known as C4S for CS), however CS can also be sulfated at 6-O (C6S), or unsulfated. A chain will frequently contain both patterns of sulfation, while oversulfated forms of CS also exist where GalNAc is sulfated at both 4-O and 6-O positions. The iduronic acid of DS can also be sulfated at the 2-O position. This heterogeneity is referred to as alterations in the “fine structure” of GAGs. These minor fine structure differences result in GAGs with overlapping but slightly different biological profiles, driving heterogeneity of GAG function. Heparan sulfate, and the structurally related heparin, are synthesized as repeating units of GlcNAc and glucuronic acid. Disaccharide blocks along the GAG chain are then N-deacetylated and N-sulfated via glucosaminyl N-deacetylase/N-sulfotransferase (NDST), which removes acetyl groups from GlcNAc and then sulfates the N-position of GlcN residues. Further potential modification steps include C5 epimerization of glucuronic acid to iduronic acid, 2-O sulfation of iduronic acid, and 6-O or (rarely) 3-O sulfation of GlcN units. The complexities of HS biosynthesis have been comprehensively reviewed by Kreuger & Kjellén. Heparin is more structurally homogeneous than HS, exhibiting a greater degree of sulfation and higher content of iduronic acid than HS, but is restricted to expression in mast cells. Keratan sulfate exists in two forms, KS-I and KS-II, with KS-I being found in skin. They differ on the basis of their linkage to their core protein, with both possessing repeating units of galactose and GlcNAc with either sugar able to be sulfated at the 6-O position.

While the biochemical processes and enzymes responsible for GAG synthesis are well known, the exact processes that regulate heterogeneity of GAG structure are still poorly understood. Current hypotheses focus on the cell altering relative expression levels of modifying enzymes to regulate structure, and that these enzymes may act together in physical complexes, a model dubbed the “GAGosome”. The variations of GAG length, post-modification patterns, GAG chain differential sulfation sites, and the formation of specific binding motifs creates complex biological signaling networks that modulate cytokines and growth factors, as well as cell/matrix interaction proteins including various collagens.

The end products of the synthesis process are complexes of GAGs attached to a protein core, known as the proteoglycan unit, which are present in virtually all mammalian cells either secreted outside the cell, inserted into the plasma membrane or stored within secretory
Figure 1 (A) Structure of GAGs found in skin and synthesis processes. Key skin sulfated GAGs heparan sulfate (HS), dermatan sulfate (DS), chondroitin sulfate (CS) and keratin sulfate (KS, KS-I form depicted) are synthesized on a protein backbone with the xylose group attached in the endoplasmic reticulum (ER), followed by the sugar groups added in the Golgi apparatus, sulfation at the trans-Golgi and finally transportation to the plasma membrane via vesicles to form transmembrane units or excreted into the extracellular space, or more rarely located intracellularly (not depicted). The sulfated GAGs covalently bound to the core protein backbone create a proteoglycan unit, with differences in core proteins, the type of GAG bound to the protein, variations in the GAG sulfation sites and number of attached GAGs resulting in different proteoglycan families and considerable within-family diversity. These GAG chains can be degraded by lyases such as heparinase or chondroitinase, while the proteoglycan unit is subject to lysosomal degradation and intracellular recycling. Hyaluronic acid is synthesized by membrane-associated HAS enzymes, resulting in long HA chains which do not bind to a protein core, but can bind other proteoglycan complexes, which can be degraded by hyaluronidase. 2S, 4S, and 6S represent sulfation at 2-O, 4-O & 6-O positions, respectively. NS represents N-sulfated (B) proteoglycans that feature prominently in skin and their commonly associated GAG formations. Sizes not to scale.
The GAG chains of extracellular and membrane-associated proteoglycans can be degraded by endosulfatases or extracellular lysases such as heparinase and chondroitinase acting on their respective GAGs, and are also internalized for lysosomal degradation or recycling, whereby the protein core can have its GAG chains trimmed or altered and re-exported to the cell membrane.

Proteoglycans are extremely diverse and are critical in a large array of biological activities, so while soluble GAG chains not in proteoglycan complexes are also capable of exerting powerful biological effects, much of the research concerning the physiological function of sulfated GAGs in skin is conducted in the context of proteoglycan interactions.

Hyaluronic acid is synthesized at the cytoplasm by three HA synthases (HAS 1–3). Cytosolic substrates UDP-Glucuronic acid and UDP-GlcNAc are added to the reducing end of the polymer by HAS, resulting in the release of UDP and the synthesis of repeating polymeric disaccharides of glucuronic acid and GlcNAc linked via a glucuronidic β (1→3) bond (Figure 1B). Hyaluronic acid synthase 1 and HAS2 yielded larger size HA ranging from 2–4×10^6 Da HA, while the HAS3 HA product typically ranges between 0.4–2.5×10^5 Da, with HAS2 predominating within skin. Following synthesis, HA molecules are directly excreted into the extracellular space, where they can act on their cognate receptors CD44 and Receptor for HA-Mediated Mobility (RHAMM). Hyaluronic acid is physiologically important for both its mechanical and biological properties. The unique helical coil conformation of HA allows it to trap up to 1000-fold of its weight in water, making HA critical for maintaining tissue structure and volume, while cross-linking of HA to proteoglycans provides stability to the ECM. Ligation of CD44 or RHAMM by HA also activates cell proliferation, migration and differentiation, significantly modulating biological pathways within the skin.

### Proteoglycans

Proteoglycans are found within the cell membrane, the ECM, and located within intracellular compartments. Cell surface proteoglycans either span the plasma membrane or are linked via a membrane-associated anchor,
those in the ECM mostly secreted but in some cases proteolytically cleaved and shed from the cell membrane. The main core protein holds sulfated GAGs chains attached via various glycosyltransferases and sulfotransferases, and can be a single type of GAG or multiple types depending on the proteoglycan. Biglycan, versican lumican and decorin are abundant in skin and feature mostly exclusive associations with their corresponding GAG type, while syndecans, a key family of membrane-bound proteoglycan in the skin, are capable of binding HS and CS, and perlecan, an extracellular matrix proteoglycan, predominately exhibits chains of HS but is also capable of mixed HS/CS possession. Proteoglycans may also differ in the number of GAG chains they can carry, with biglycan typically holding two chains of either CS or DS (with DS being more common), while aggrecan can hold in excess of 100 chains. Further distinction can be made on the basis of core protein size, with the small leucine-rich proteoglycan (SLRP) family of ECM-associated proteoglycans such as decorin, lumican and biglycan exhibiting protein cores of 40–60 kDa with 10–12 leucine-rich repeat motifs, and are highly important in skin. This GAG variability and stoichiometric variation creates a confluence of factors leading to an extremely high degree of variation within GAG-proteoglycan association.

Proteoglycan production is governed by an extraordinary complex set of processes encompassing transcription factors, glycosyltransferases and sugar nucleotide transporters, many of which remain poorly understood. The most prominent upstream effectors of proteoglycan production are growth factors and cytokines, which can induce differential regulation of proteoglycans in tissue-specific and dose-dependent ways. Interleukin-1β, for example, decreases versican synthesis in skin fibroblasts, but upregulates it in lung fibroblasts, while IFN-α, IFN-β, IFN-γ, TGF-α, TGF-β, IL-2 and GM-CSF all exhibit differential dose-dependent effects on total GAG induction within human dermal fibroblasts. Fibroblast growth factor (FGF) family members are particularly prominent regulators of proteoglycan expression, especially for SLRP family members. Within dermal fibroblasts, FGF-2 decreases biglycan synthesis while increasing decorin, and FGF family members are particularly important regulators of syndecans via FGF-inducible response elements. The large numbers of cytokines and growth factors that differentially regulate production of any given proteoglycan suggests that concentration gradients across different permutations of growth factors are critical in governing proteoglycan synthesis and composition.

Glycosaminoglycan/Proteoglycan Physiological Role Within Skin

Glycosaminoglycans make up 0.1–0.3% of total skin weight, with ~6–7-fold more GAG present in the dermis compared with epidermis. While exact numbers range between studies and the skin site examined, HA comprises approximately half of all GAG within total skin from young donors, with sulfated GAG bound in proteoglycan complexes constituting the other half. Of the sulfated GAGs, CS/DS predominates with an overall trend to slightly higher levels of DS, while there are much lower levels of HS and KS. These estimates are consistent with GAG proportions in the dermis, however within the epidermis there are relatively high levels of C4S, HS and low levels of KS expressed, while the basal epidermis is the only site containing C6S. Hyaluronic acid within the epidermis is mostly extracellular and located at the upper spinous and granular epidermal layers, although there is some intracellular HA located in the basal layer.

Hyaluronic acid forms an important structural component of the ECM, acting as a scaffold for macromolecules which decorate the HA chains in a bottlebrush formation, with ECM areas containing thinner fibers showing highest levels of HA deposition. HA can similarly bind proteoglycans such as aggrecan, facilitating the biological functions of extracellular proteoglycans. The high amounts of water bound by HA are critical for maintaining adequate hydration within the skin, promoting both physiological function of the skin and the maintenance of cosmetic skin quality. The signaling properties of HA within the skin, as in other tissues, is to a large degree a function of the molecule size. High-molecular weight HA (HMW-HA) suppresses inflammation and angiogenesis, while low-molecular weight HA (LMW-HA) created from the cleavage of HA within the site of injury can promote inflammation and scar formation, and increase angiogenesis. Low-molecular weight HA however is able to function as an antioxidant scavenger, and promotes wound healing through ROS quenching. HA is able to facilitate the movement of Langerhans cells through the epidermis by binding CD44 found on the surface of these cells, and therefore may help promote immune homeostasis given the well-known immune tolerance functions of Langerhans cells. Ligation of keratinocyte-associated CD44 by HA is...
Glycosaminoglycans/Proteoglycans in Skin Aging

The biological phenomenon of skin aging can be divided into two major categories, intrinsic and extrinsic aging, based on their causes and observed clinical signs. Intrinsic aging results from internal physiological factors that are largely inescapable consequences of the passage of time and manifests as fine lines, thinned epidermis, and gradual dermal atrophy. Extrinsic aging is the sum of all external aggressors such as UV light, pollution and cigarette smoke exposure that results in coarse wrinkles, loss of elasticity and rough texture.19,64,65

Total sulfated GAG levels are reduced within intrinsically aged skin compared with young samples.56 Furthermore the relative proportions of GAG are also altered, with intrinsically aged skin samples demonstrating decreases in HS and CS levels, particularly CS in the basal lamina, while conversely KS and DS are increased.19,65 Expression of CS is higher in fetal skin when compared to mature skin, which may contribute to the scarless healing ability of fetal skin.67 In contrast to intrinsically aged skin, photoaged skin shows an increase in total sulfated GAG levels within males, consistent with data showing elevated dermal CS in a cohort of volunteers subjected to either short- or medium-term UV exposure.68 Beyond GAG levels found within skin, the pattern of GAG deposition is also critical. The GAGs within sun-damaged skin are deposited on the elastotic material of the papillary...
dermis as opposed to between collagen and elastin fibers of normal skin, which may suggest attenuated collagen fibril organization functions for GAG within photoexposed skin.

Hyaluronic acid is reduced in adult skin compared with juvenile skin, alongside downregulation of CD44, HAS1, HAS2 and RHAMM. Within photoaged skin there are similarly decreased levels of HAS1, CD44 and RHAMM, but also an increase of low mass HA. The observed changes are mirrored by in vitro studies on human fibroblasts, which also demonstrate attenuation of HAS2 mRNA by UVB exposure, a process mediated by collagen fragments. While the exact contribution of changes in HA to the aged skin phenotype remains under question, the dysregulation of HA homeostasis in both intrinsic and extrinsic aging is clear.

Among proteoglycans, perlecan expression within the skin is reduced during physiological aging, and aged keratinocytes exhibit dramatically reduced perlecan mRNA transcripts. Interestingly, the same study demonstrated that addition of exogenous perlecan to the culture media of 3D organotypic skin reconstructed with aged keratinocytes results in epidermal thickening, suggesting perlecan to be a potential target for anti-aging intervention.

Figure 2 Key biological activities of GAG & proteoglycans in skin. (A) Proteoglycans act to present chemokines/cytokines to their cognate receptors. (B) GAG chains on proteoglycan act as co-receptors for growth factor receptors (GF-R), potentiating GF-R signaling. (C) They can also sequester growth factors, protecting them from proteinase activity and thermal instability which can then be later released to activate GF-R, and (D) potentiate autocrine receptor signaling and clustering. These pathways result in proteoglycans holding important roles in skin cell proliferation, migration, differentiation and inflammatory signaling, all of which critical for skin homeostasis and wound repair. Proteoglycans and HA are critical for the formation and structural stability of the ECM, and are particularly important in (E) ECM water retention, ensuring adequate cutaneous hydration. (F) collagen fibril assembly, and (G) ECM formation and structural stability. Soluble GAGs, particularly HA, are capable of directly interacting with the membrane-bound receptors, shown here as HA interacting with CD44 that plays a critical role in dermal fibrogenesis, regulating collagenolysis and ECM remodeling. (H) (I) Proteoglycan endocytose external factors such as cytokines and chemokines, making them available intracellularly or transporting them across the cell membrane for degradation.
Absolute proteoglycan levels need not change within aging for their function to be altered or attenuated. Li and colleagues found that decorin levels within aged skin remain constant, but decorin from aged donors displays shorter GAG chains compared with those from younger skin, possibly contributing to skin fragility.\(^{53}\) Decorin levels are reduced in photoaged skin however, with fibroblasts isolated from photodamaged sites producing 46% less mRNA under basal conditions.\(^{69}\)

The complexity of GAG and proteoglycan chemistry and differential changes during aging underscores the importance of not only examining changes in absolute levels of these factors, but also their altered structures, functional abilities and localization within the skin. The broad distribution and critical role of GAG and proteoglycans within skin suggests they are likely major players within skin aging, and therefore represent a promising target for anti-aging intervention. A comprehensive list of changes of GAG and proteoglycans within intrinsic and extrinsic aging is given in Table 2.

### Proteoglycan Regulation of Growth Factor Activity

Growth factors encompass a broad family of proteins that can act in autocrine, paracrine or endocrine manner to stimulate cell migration, proliferation and differentiation.\(^{74}\) While there are many growth factor families as determined on the basis of structure, receptor specificities and functional properties, the Fibroblast Growth Factor (FGF) family, Epidermal Growth Factor (EGF) family, transforming growth factor-beta (TGF-\(\beta\)) superfamily, platelet-derived growth factor (PDGF) family, and vascular endothelial growth factor (VEGF) family are all particularly important within skin due to their roles within skin homeostasis and wound healing.\(^{75}\)

The powerful ability of growth factors to promote re-epithelialization, angiogenesis, fibroblast proliferation and survival has created interest in their activity to improve the cosmetic quality of chronologically and photo-aged skin.\(^{76}\) The FGF family, consisting of 22 different molecules divided into 7 discrete subfamilies, as well as EGF are of potential interest due to their mitogenic and motogenic properties\(^{77}\) and are the basis for the majority of growth factor-associated anti-aging approaches. Within the FGF family, acidic FGF (aFGF/FGF1) and basic FGF (bFGF/FGF2) have been of particular cosmetic interest and feature in a large number of cosmetic products that claim an anti-aging effect.\(^{77}\) Keratinocyte Growth Factor (KGF/FGF7) acts to induce epidermal thickening and therefore may also be particularly beneficial for epidermis-related endpoints.\(^{78}\)

While there is evidence of growth factor efficacy on skin quality, especially when combined with enhanced delivery systems such as microneedles or protein encapsulation to improve bioavailability,\(^{79–81}\) the effectiveness of growth factor topical administration is constrained due to their large size and susceptibility to proteinases. Other approaches such as increasing the stabilization of endogenous growth factors offer the potential to circumvent these issues, acting to increase growth factors levels within the skin without directly increasing growth factor production through sequestration in a stable conformation, resulting in enhanced biological activity.\(^{82–84}\) This is particularly the case with many FGF family molecules, which demonstrate a high degree of thermal instability that attenuates their signaling ability.\(^{85}\)

Extracellular-matrix proteoglycans and GAG fragments (particularly of HS\(^{86,87}\)) are critical for regulating growth factor pathways and stabilize growth factors within the skin through protection from degradation, and also increase the affinity of growth factor for its cognate receptor and stabilize the receptor-ligand complex.\(^{88}\) Heparan sulfate proteoglycans in the skin act to bind and regulate growth factors through syndecans at the cell surface, or via perlecans at the basement membrane of the DEJ.\(^{74,89,90}\) Hyaluronic acid similarly binds TGF-\(\beta\), protecting it from tryptic degradation and therefore modulating TGF-\(\beta\) bioavailability.\(^{91}\) After their liberation from ECM-associated sequestration, FGF ligands bind to their cognate receptor in a HS-proteoglycan-dependent manner.\(^{75}\) Fibroblast Growth Factors are dependent on HS-proteoglycan signaling in vivo via bridging between the contact receptor and ligand, cross-linking and stabilizing the complex via the 6-O-sulfate group on the HS/heparin GlcN.\(^{92,93}\) Consequently, disruption of HS-proteoglycan function causes a loss of FGF signal transduction and greatly attenuated cell migration.\(^{94}\) The multifaceted mechanisms through which GAG, and HS-proteoglycans in particular, act to stabilize growth factors and facilitate their biological activity demonstrate that cosmetic interventions that increase cutaneous GAG content may also act to potentiate the endogenous growth factor effect.

### Cosmetic Approaches for Anti-Aging GAG/Proteoglycan Modulation

Topical strategies for targeting GAGs can broadly fall into two categories; direct addition of GAGs into topical
Table 2 Changing During Intrinsic and Extrinsic Aging of GAG and Proteoglycans Commonly Found in Skin

<table>
<thead>
<tr>
<th>Skin Layer</th>
<th>Intrinsic Aging Modulation</th>
<th>Extrinsic Aging Modulation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HA and related molecules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>Epidermis</td>
<td>↓,66 NC141</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓,66 ↓ (female),66 NC141</td>
</tr>
<tr>
<td>HAS</td>
<td>Epidermis</td>
<td>↓HAS2,66 ↓HAS1 ↑HAS3 mRNA total skin70</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓HAS266</td>
</tr>
<tr>
<td>CD44</td>
<td>Epidermis</td>
<td>↓66</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓66</td>
</tr>
<tr>
<td>RHAMM</td>
<td>Epidermis</td>
<td>↓ Total skin mRNA70</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td></td>
</tr>
<tr>
<td><strong>Sulfated GAGs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Sulfated GAG</td>
<td>Epidermis</td>
<td>↓,66 ↓ (female)66</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓66</td>
</tr>
<tr>
<td>CS</td>
<td>Epidermis</td>
<td>↓ (C6S)37</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td></td>
</tr>
<tr>
<td>DS</td>
<td>Epidermis</td>
<td>↑37</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↑37</td>
</tr>
<tr>
<td>KS</td>
<td>Epidermis</td>
<td>↑37</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td></td>
</tr>
<tr>
<td>HS</td>
<td>Epidermis</td>
<td>↓66</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓66</td>
</tr>
<tr>
<td><strong>Proteoglycans</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Versican</td>
<td>Epidermis</td>
<td>↓ total skin holding ability of GAG &amp; altered sulfation,73 NC mRNA,143 ↓(male)66</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td></td>
</tr>
<tr>
<td>Decorin</td>
<td>Epidermis</td>
<td>LE63</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓66 ↓ GAG holding ability53</td>
</tr>
<tr>
<td>Biglycan</td>
<td>Epidermis</td>
<td>↓ total skin,19 ↓ mRNA70</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>NC aged fibroblasts145</td>
</tr>
<tr>
<td>Perlecan</td>
<td>Epidermis</td>
<td>↓(female)56</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓(female)56</td>
</tr>
<tr>
<td>Lumican</td>
<td>Epidermis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓aged fibroblasts145</td>
</tr>
<tr>
<td>Syndecan</td>
<td>Epidermis</td>
<td>↓Syndecan-1, NC Syndecan-466</td>
</tr>
<tr>
<td></td>
<td>Dermis</td>
<td>↓Syndecan-1, NC Syndecan-466</td>
</tr>
</tbody>
</table>

**Notes:** ↑ denotes increase; ↓ denotes decrease; NC denotes no change; LE denotes low expression, with the corresponding reference for the data; Blank means no data; Total skin denotes epidermis and dermis not separately analyzed; SE means data obtained in solar elastosis.
formulations, or through more indirect means such as administration of molecules that potentiate the production or release of GAGs within the skin. Each approach possesses strengths and weaknesses; topical GAGs preparations act directly but face inherent issues of skin penetration and stability, while indirect approaches utilizing smaller molecules may have greater ability to penetrate past the stratum corneum, although a high degree of potency is required to significantly modulate GAG activity.

Topical Application of GAGs

Topical use of HA is a safe and effective mainstay of the cosmetics and aesthetics industry, with both topical formulations and injectable HA being popular (extensively reviewed by Bukhari and colleagues, including use of HA fillers beyond the scope of this review). Daily use of over-the-counter formulas containing high levels of HA results in clear reductions in wrinkle depth, skin laxity, skin dehydration with an increase in barrier function while displaying minimal adverse events, demonstrating HA to be an accessible and safe skincare solution. Large molecular weight HA will not penetrate the skin however, leading to the development of preparations containing HA fragments of varying sizes to improve skin penetration. Studies examining the degree of penetration past the stratum corneum of these HA molecules have produced conflicting results. Convincing data from Brown and co-workers using radiolabeled HA on hairless mice and a human volunteer suggested penetration past the stratum corneum, which the authors speculated to be the result of active transport. Conversely, Zhang and colleagues (2019) demonstrated minimal penetration of HA in pig skin without additional promoters of penetration such as spicules and liposomes. Despite these questions concerning skin penetration into the deeper layers of skin, penetration into the stratum corneum is plausible and may be consistent with clinical studies demonstrating efficacy for LMW-HA formulations.

Pavicic and co-workers utilized a 0.1% HA topical formulation containing HA ranging between 50–2000 kDa, finding formulas with LMW-HA in particular were associated with a reduction in wrinkle depth. While these smaller HA fragments are still large molecules in the context of cutaneous bioavailability, biotinylated intermediate size (50–400 kDa) HA fragments were found in the dermis of hairless mice, consistent with some degree of skin penetration potentially via the hair follicle. Of particular note, intermediate size HA fragments mediated an increase in keratinocyte proliferation via a heparin bound-EGF and EGFR-activation-dependent mechanism in vitro, further implicating growth factor modulation in the positive biological activity of GAG in cosmetic skin quality.

Similar approaches have utilized HS fragments for topical use. Gallo and colleagues used a low molecular weight HS (LMW-HS)-containing formulation to reduce signs of facial aging on photodamaged skin, while a similar preparation reduced the appearance of hyperpigmentation and wrinkles when applied to the periorbital area. Colvan and colleagues similarly demonstrated that an eye cream containing LMW-HS and a blend of naturally derived extracts achieved skin rejuvenation by improving appearance of periorbital hyperpigmentation, puffiness, and fine and coarse wrinkles. Ito and colleagues (2017) examined fractions of Porcine Placental Extract (PPE), which has a long history of use for both cosmetic and medicinal purposes. They found the medium-to-high molecular weight fractions to be rich in heparin/HS and CS, which potentiated FGFR signaling and protected FGF1 growth factor from trypsin digestion in a similar way to control heparin. Low molecular weight fractions of PPE were also able to potentiate FGFR signaling and promote cell proliferation, perhaps suggesting these fractions contained bioactive GAG fragments. Such approaches clearly demonstrate the ability of GAGs to modulate growth factor signaling, and suggest that growth factor modulation may be a potential mechanism behind LMW-HS efficacy within skin.

Despite these promising data, skin penetration will likely remain a formulation challenge for topical penetration of exogenous GAG preparations. Hydrogels, nano/microemulsions, liposomes and conjugation strategies have all been employed to increase the bioavailability of topical HA, although these technologies mostly remain at the experimental stage (reviewed in). Robust penetration into deeper layers of the skin likely requires some form of assisted delivery however, with microneedling through the use of dermarollers, gliding or stamping microneedle devices, radiofrequency-based thermal needles, or fractionated lasers most commonly used. A related approach involves fabricating microneedles with HA itself to be applied to the skin in patches, resulting in clinical improvements in aging endpoints such as wrinkling and dermal density, and forms the basis of a delivery system for other anti-aging compounds.
Raw Material Approaches to Modulate GAG Levels in the Skin

Indirect approaches to increase GAG content, particularly HA, are a common skincare raw material development strategy, however it is often difficult to determine if the modulation of GAG is a cause or consequence of the improved skin quality imparted by a treatment. Topical treatment with alpha hydroxy acids (AHA) for skin peeling results in increasing total GAG content\(^{110}\) and HA levels\(^{111}\) within the regenerated skin, correlating improved skin quality with elevated GAG levels. While improved skin appearance following skin peel treatment is consistent with the expected biological outcomes following restoration of GAG levels and function in aged skin, there is no evidence they act in a specific manner to induce GAG synthesis as opposed to synthesis occurring during AHA-induced general skin repair processes.

Direct modulation of GAG levels within the skin via topical small molecules or extracts has two possible strategies: downregulate factors that promote GAG degradation, or to increase GAG levels through the promotion of GAG synthesis. While the exogenous addition of hyaluronidase is common within medical aesthetics to break down injected HA fillers where the results did not match expectation or in cases of allergic reactions to the filler, it also represents a target for increasing endogenous HA levels within the skin. Sodium copper chlorophyllin is a relatively common cosmeceutical ingredient as a colorant, antioxidant and anti-bacterial, however it has also been demonstrated to inhibit hyaluronidase in vitro.\(^{112}\) Clinical studies have demonstrated that topical treatment using sodium copper chlorophyllin complexes improves the cosmetic quality of photoaged skin and increases cutaneous GAG levels, which is speculated by the authors to be the result of hyaluronidase inhibition.\(^{112-114}\) Despite these encouraging results, strategies aimed at modulating GAG levels in skin more commonly target directly increasing GAG production.\(^{4}\)

Expression of HAS gene mRNA or HA production is one of the most common experimental endpoints for cosmetic raw material (RM) evaluation, and thus compounds or extracts that exhibit effects on this pathway are not few. Transcriptional regulation of the HAS1–3 genes is mediated by a broad family of growth factors and cytokines, with EGF, FGF, TGF-β and IFN-1β particularly prominent.\(^{115,116}\) In general terms, factors that increase keratinocyte proliferation and migration such as EGF and KGF stimulate HAS2 and HAS3, while those that suppress keratinocyte growth and increase differentiation such as TGF-β decrease HA synthesis.\(^{117}\) Hyaluronic acid synthesis can also be regulated by control of precursors UDP-Glucuronic acid and UDP-GlcNAc, post-transcriptional modulation of HAS activity or HAS phosphorylation,\(^{116}\) resulting in a diverse set of mechanisms through which cosmetic materials can modulate HAS expression and HA production within skin. Table 3 summarizes cosmetic preparations with clinical evidence of efficacy that are also known to increase HA levels or act on the HA pathway. The effect of retinol family compounds on cutaneous GAG is particularly complex. Tretinoin (all-trans retinoic acid) and isotretinoin are typically used for medical aesthetics/dermatological purposes, while retinol and retinol esters are commonly found in cosmetic formulations. The HAS promoter region contains response elements for the retinoic acid receptor and thus is directly regulated via tretinoin,\(^{118}\) however signaling via EGF-R and HB-EGF is also an important aspect of retinoid-induced HA production and HAS induction within keratinocytes.\(^{117}\)

Tretinoin also increases the synthesis of sulfated GAGs in cultured human fibroblasts,\(^{119}\) as well as within animal models.\(^{120}\) Margelin and colleagues also found that topical tretinoin treatment resulted in increased GAG synthesis in normal mice, particularly of DS. Curiously, tretinoin prevented the decline of GAG levels within the skin of UVB-exposed animals, although given the altered distribution of GAG deposition within UV exposed skin\(^{59}\) one may speculate that UV-induced aberrant GAG deposition on the elastic material of the papillary dermis was declining as the skin recovered, while beneficial GAG on collagen and elastin fibres was increased by tretinoin treatment. The increase of GAG levels within animal models are consistent with the clinical work of Kafi and colleagues, who found that treatment with a 0.4% retinol formulation increased total cutaneous GAG levels as determined by immunostaining.\(^{121}\) Chajra and co-workers utilized a similar strategy for boosting sulfated GAG levels with a formulation containing GAG precursors and synthesis intermediaries, finding it increased sulfated GAG levels within cultured human skin fibroblasts and ex vivo human skin, while improving dermal structure of ex vivo skin samples and increasing skin smoothness in a cohort of female volunteers.\(^{122}\) Jasmonic acid derivatives (JAD) have also been demonstrated to increase proteoglycan expression and modify GAG fine structure in skin, as well as potentiate KGF signaling. Consistent with these in vitro data, JAD treatment
promotes re-epithelialization clinically within a suction-cup blister model of wound healing.\(^{164}\)

A key approach for modulation of GAGs involves the use of xylosides, members of the glycoside family that consist of a xylose attached to an aglycone that can act as competitors for GAGs to attach to their core protein. This results in synthesis of proteoglycans that have fewer GAG chains attached, while the xyloside can act as the core tetrasaccharide linker for the assembly of soluble GAG, resulting in GAG being synthesized onto the xyloside itself and subsequently secreted from the cell.\(^{123}\) Xylosides tend to make 5–20 times more GAG chains than endogenous core proteins, resulting in greatly potentiated free GAG levels.\(^{124}\) The most successful for skincare application has been C-xyloside, which is synthesized according to green chemistry principles\(^{125}\) and commercialized under the name Pro-Xylane\(^{\text{TM}}\).

Using a 2D fibroblast culture system, Pineau and co-workers compared the GAG-inducing properties of C-xyloside to those of β-xylosides, known potent GAG inducers (particularly of CS, DS and in some cases HS), but have poor stability that compromises their biological utility.\(^{126–128}\) C-xyloside induced an overall increase in fibroblast GAG synthesis profile and magnitude similar to that of β-xyloside, with particularly increased levels of single chain GAGs likely to be DS.\(^{129}\)

### Table 3 Cosmetic RMs with Clinical Data That Act on HA

<table>
<thead>
<tr>
<th>RM</th>
<th>HA Activity</th>
<th>Clinical Benefit</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAD</td>
<td>↑ HAS2 &amp; HAS3 mRNA, No change in CD44 ↑ HA expression (3D model)</td>
<td>Improvements in the appearance of wrinkles, texture, and pores</td>
<td>([148,149])</td>
</tr>
<tr>
<td>Tetrapeptide GEKG</td>
<td>↑ HAS1 mRNA (primary human foreskin fibroblasts), ↑ HA expression (ex vivo IHC)</td>
<td>141% elasticity on inner forearm, ↓ 42% skin wrinkle depth, ↓ 9.5% periorbital wrinkle</td>
<td>([150])</td>
</tr>
<tr>
<td>Peptide pal-KTTS</td>
<td>↑ HAS1 mRNA (primary human fibroblasts), ↑ HA expression (ex vivo IHC)</td>
<td>↓ 36% elasticity on inner forearm ↑ 18% skin wrinkle depth</td>
<td>([150])</td>
</tr>
<tr>
<td>Isosorbide dicaprylate</td>
<td>↑ CD44 mRNA (3D model)</td>
<td>Improvement in skin hydration (34.5% for moderate dry skin and 133% for severe dry skin), 15% reduction in TEWL</td>
<td>([151])</td>
</tr>
<tr>
<td>N-acetylglucosamine</td>
<td>No effects on HAS-1/2/3 mRNA (HDF), ↑ HA synthesis (HDF)</td>
<td>Reduced the appearance of facial hyperpigmentation</td>
<td>([152,153])</td>
</tr>
<tr>
<td>N-acetylcysteine</td>
<td>↑ HAS and hyaluronidase mRNA (HDF)</td>
<td>Improvement in skin hydration Reduction in TEWL</td>
<td>([154,155])</td>
</tr>
<tr>
<td>L-ascorbic acid</td>
<td>↓ HAS2, CD44, HYAL1 &amp; HYAL2 mRNA, No change in HAS1 and HAS3 mRNA (3D model)</td>
<td>Improvements in skin wrinkling and skin roughness</td>
<td>([156–158])</td>
</tr>
<tr>
<td>Retinoic acid and derivatives</td>
<td>↑ Binding to HA promoter, ↑ CD44 expression, HA production (NEK)</td>
<td>Improvements in skin wrinkling, barrier function and hydration</td>
<td>([117,118,159])</td>
</tr>
<tr>
<td>Epigallocatechin-3-Gallate</td>
<td>↑ HA expression (IHC, ex vivo skin)</td>
<td>Reduced redness and flattened scars</td>
<td>([160])</td>
</tr>
<tr>
<td>Sanguisorba officinalis root extract</td>
<td>↑ HMW-MA synthesis (HDF)</td>
<td>Improved skin elasticity, reduced wrinkling</td>
<td>([161])</td>
</tr>
<tr>
<td>Isosorbide dicaprylate</td>
<td>↑ CD44 mRNA (3D skin)</td>
<td>Improvement in skin hydration (34.5% for moderate dry skin and 133% for severe dry skin)</td>
<td>([151])</td>
</tr>
<tr>
<td>HAS</td>
<td>↑ HAS mRNA</td>
<td>Improvements in fine lines/wrinkles, tactile roughness, and skin hydration</td>
<td>([162])</td>
</tr>
<tr>
<td>TRMT</td>
<td>↑ HAS mRNA, ↓ Hyaluronidase mRNA (Human Epidermis)</td>
<td>Improvements in fine lines/wrinkles, brightness, texture and hydration</td>
<td>([163])</td>
</tr>
</tbody>
</table>

**Notes:** ↑ denotes increase in expression; ↓ a decrease; 3D skin denotes data obtained in 3D reconstructed skin models; IHC denotes immunohistochemistry; HDF denotes Human Dermal Fibroblasts; NEK denotes Normal Human Primary Keratinocytes.
promotes production of CS/DS in keratinocytes with the majority of secreted GAG being DS, with these chains being considerably shorter than native GAG and exhibiting altered sulfation patterns. Similar trends were observed in a reconstructed dermis model, with C-xyloside greatly potentiating the secretion of free CS/DS which featured reduced chain sizes, increased O-sulfation, and altered iduronic acid content and distribution. While there was no reduction in proteoglycan-associated GAG chain levels unlike that imparted by other xylosides, treatment with C-xyloside also resulted in shortened GAG chain length and altered sulfation patterns, particularly in the CS/DS 4-O/6-O sulfation ratio (Figure 3). Similarly, while HS levels were unchanged by C-xyloside treatment, there was a strong reduction in sulfation content, particularly 6-O sulfation (Figure 3). C-xyloside promoted FGF-10-dependent keratinocyte migration and cell proliferation within a 2D keratinocyte scratch test model in a similar manner to groups treated with DS directly. These results are likely due to C-xyloside increasing DS levels within the culture that are essential for FGF-10 function on keratinocytes, and provide proof-of-concept for the ability of C-xyloside to support in vitro growth factor activity via GAG production.

C-xyloside treatment within organotypic 3D reconstructed skin resulted in improved preserved skin architecture, with potentiated deposition of key DEJ proteins laminin 5 (which
anchors microfilaments that connect the hemidesmosomes and the lamina densa, Type IV collagen (a major component of the lamina densa), and Type VII collagen (corresponding to anchoring fibrils). These proteins collectively act to strengthen the attachment of keratinocytes to the basement membrane, promoting dermal-epidermal adherence required for skin cohesion and resistance to mechanical stress.

Similar data have been noted within the organotypic model of corticosteroid atrophic human skin, where repeated treatment with C-xyloside restored the levels of CD44, perlecan and syndecan 1 and 4 expression back to those observed within control skin.

These in vitro study results of the beneficial effects of GAG modulation have been extended to clinical findings. Three months of daily C-xyloside treatment results in improvements in clinical aging endpoints, with the development of a more homogeneous and regular lamina densa of the DEJ as determined by transmission electron microscopy evaluation, and a concomitant increase in laminin-332 and its α6 integrin subunit which are implicated in DEJ resistance to mechanical stress.

These data are consistent with clinical results using a topical formulation containing C-xyloside and an AGE-inhibiting blueberry extract in a cohort of 20 type II-diabetic female patients, a group that demonstrates increased levels of AGE and therefore represents a clinical model of accelerated aging. Twice daily treatment with the formula over 12 weeks resulted in significant improvements in clinical endpoints of skin quality such as fine lines, firmness, radiance, skin tone evenness, smoothness and overall skin appearance.

Similarly, a clinical study utilizing a multi-modal facial serum containing C-xyloside, HA and a number of natural extracts and examining wrinkle dimensions (length, depth and width), skin density and transepidermal water loss (TEWL) on a 59-person cohort of women with mild-to-moderate facial damage demonstrated significant improvements across all clinical endpoints measured, and by week 12 there were also significant improvements in SC hydration and TEWL, as well as increased skin HA levels, HAS2 and Col1α1.
within biopsied skin sections isolated from the volunteers.\(^{139}\)

Finally, a multi-center, blinded and randomized study of 240 healthy, post-menopausal women using a skincare complex with a backbone of 3% C-xyloside exhibited statistically significant improvements in facial ptosis, neck folds, nasolabial folds, skin radiance and complexion evenness as determined by blinded clinical assessment, with an accompanying improvement in skin lipid profile.\(^{140}\) These data collectively demonstrate the efficacy of approaches aimed at modulating endogenous sulfated GAGs within the skin, and may form the basis of future developments focusing on CS/DS and/or HS. The key approaches for increasing GAG levels within the skin, and published resultant changes in skin physiology are summarized in Figure 4.

**Conclusion**

Glycosaminoglycans form an integral part of the skin, and the alteration of GAG and proteoglycan form and function during both intrinsic and extrinsic aging demonstrates their utility as a target for improving age-associated declines in skin quality. While the benefit of direct topical GAG administration such as HA-containing formulas is well established, approaches utilizing molecules or extracts to promote GAG release within the skin such as C-xyloside are also clearly beneficial, and represent a promising target for future development of topical skincare solutions.

**Acknowledgments**

We would like to thank Dr Diah Bramono for the helpful discussions and critical reading of the manuscript, and Dr Isabelle Castiel for her guidance.

**Disclosure**

Ms Wang was an employee of L’Oréal Research & Innovation at the time the study was conducted. Mr Neo and Dr Betts are employees of L’Oréal Research & Innovation. The authors report no other conflicts of interest in this work.

**References**


